Zheng bin, born in May 1987 in Chongqing, Ph.D., is a postdoctoral associate professor and postgraduate supervisor of Karolin Medical College, Sweden. He has a Bachelor of Engineering in bioengineering, a master of medicine in public health and a doctor of Science in biology. After that, he visited Berlin Free University in Germany and Karolinska Medical College in Sweden and engaged in postdoctoral research. In 2018, he joined the school of medical engineering of Tianjin University, mainly engaged in the research of material chemistry and intelligent living cell drug development, and made a series of research progress in tumor, infectious diseases, diabetes and neurodegenerative diseases by using biomaterials, gene editing, photogenetics and other means. In the past five years, 25 SCI papers have been published, and 18 research-oriented SCI papers (15 papers of top journals in the first district of Chinese Academy of Sciences) have been published in advanced materials (if: 27.398), ACS Nano (if: 14.58) and other top journals at home and abroad by the first / corresponding author, with cumulative impact factor > 200. He has been authorized 3 invention patents, more than 60 of which are under trial. On average, he has cited nearly 20 times for each paper, and has published several conference papers and signed SCI papers. He has also acted as reviewer of several international well-known journals. A number of research results have been quoted and reported by Johns Hopkins University, National University of Singapore, Nanyang Technological University, science and technology daily, science net, today's headlines, x-mol science website and many other institutions and media.